TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total Urinary Output at 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fluid Balance at 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Who Experienced Emesis
Endpoint domain: Adverse events/effects
Primary endpoint: visual analogue scale for pain during rest and on moving the jaw
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fonseca's scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: improvement in child's oral hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental area under the curve of postprandial glucose excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cystocele recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radial artery graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean daily number of physician visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adverse Event Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: number of patients able to successfully withdraw from PPI treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Short-interval Intracortical Inhibition (SICI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of postoperative cognition dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of postoperative delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropsychological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 1 year major adverse kidney events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC) of PEG-Intron at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Female Sexual Function Index (FSFI) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reporting Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total Opioid Consumption During the First 72 Hours Postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Opioid Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of MNTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TWEAK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immobilization effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: postoperative time to first anal exhaust
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: the cumulative dose administered in the patient-controlled mode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective bolus times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in self-reported function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite endpoint of mean score in cognitive assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraoperative hemodynamic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic contribution of exome sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening for amblyogenic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone formation around dental implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Immune Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-gE Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects unable to attend all sessions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Aesthetic effect assessed by GAIS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Postsurgical Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of erythema and edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Biometry prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance during a 5-minute all-out cycling test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Adverse Events and/or Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of trabectedin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of ketoconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric Emptying Half-time (T1/2) of Solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric Emptying Lag Time (T-lag) of Solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful outpatient treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving IGA score of clear or almost clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intestinal fractional calcium absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Receiving HCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Natural progression of PCT following hemorrhagic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Seropositivity Against Each Serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) Against Each Serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of App Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Lessons Completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Interactions (Text/Phone) With Health Coaches
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Type 1 or type 4b myocardial infarction or cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Rates of study enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Salivary levels of PGE2 and PGI2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective best response rate (complete remission and partial remission)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Picture-naming Accuracy Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection of the sentinel lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: matching between the sentinel lymph node detected by the novel method and the control one
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of life impact due to allergic rhinitis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Micropore Closure Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Graft function (GFR difference of 10 ml/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of WPP-201
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Hereditary Cancer Syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy rate of the model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of the model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of tissue background ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of respiratory sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival without moderate or severe disability
Endpoint domain: Mortality/survival
Primary endpoint: Mortality rate on the 7th day
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of All Cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Device and/or Cardiovascular Related Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in average number of days with migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neural processing during feedback based learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Satisfaction and Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: exercise program engagement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Alterations in circulating placenta-secreted markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in placental histopathology for markers of malperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal tolerated dose (MTD) of SAR260301 in monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximal tolerated dose (MTD) of SAR260301 in combination with vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks After Stopping All Study Drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Test Results Outside the Normal Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence, severity, and interference of physical and psychological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Hospital Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Anatomical variation of the sympathetic ganglions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measurement of aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention tolerance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intervention adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum Plasma Concentration (Cmax) of S-Warfarin and R-Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximal Plasma Concentration (Tmax) of S-Warfarin and R-Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)] of S-Warfarin and R-Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pad use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reoperation Rates
Endpoint domain: Adverse events/effects
Primary endpoint: Change of concentration of Serum Amyloid A (SAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of concentration of paroxonase-1 (PON-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in p16 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Progression: Survival
Endpoint domain: Mortality/survival
Primary endpoint: Overall Incidence of Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Tumor Lysis Syndrome (TLS)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Amblyopic-eye Visual Acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Abdominal Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HBAIc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Troponin-T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Hsp72 protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial eNOS protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Histological findings in placentas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Best response after consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Late Onset Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of Active T regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients without severe complications
Endpoint domain: Adverse events/effects
Primary endpoint: CPEAK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: portal vein pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: portal vein flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: hepatic artery flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Grade 4 TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: New Bone Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent of time maintained within 0.5°C range of the 35°C input target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total peripheral blood gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tregs and Tconvs T cell receptor repertoire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokines and chemokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Child Health and Illness Profile - Child Edition (CHIP-CE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean QTcF interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of beta-lactam immediate allergy
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Urine Protein to Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Effectiveness of studied moderators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Log Transformed P100 Amplitude of TEPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Colonoscopy results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in positive experiences of the caregiver
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Atrial fibrillation freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spherical Equivalent Refractive Error (SERE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Axial Length (AL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of vocal cords
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of right-to-left shunt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response profiles of MRI signals for menstrual pain phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response profiles of MRI signals associated with NSAID-resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotype consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal mucosal morphometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Death after a first ST elevation or non ST elevation MI
Endpoint domain: Mortality/survival
Primary endpoint: Preventive Medication Actions (PMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Experiencing Acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of scintigraphic improvement at 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of VT primary occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of time spent with blood glucose between 3.9 and 8.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in probing pocket depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 7 clinical response defined as PUCAI <35
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Zarit Burden Interview-12 (ZBI-12)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Patient Health Questionnaire-4 (PHQ-4)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: upper-extremity Fugl-Meyer Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Insulin Exposure (%AUC[0-60])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in New York Heart Association (NYHA) classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with more than 5 Ω of impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bowel Cleansing Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Annualized bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of spontaneous bleeding episodes per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infusions of Afstyla® required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pregnancy and delivery rates
Endpoint domain: Mortality/survival
Primary endpoint: Injecting Risk Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients reported symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Secondary infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change of cuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron Deficiency Anemia (IDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: General Anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Iodine status of participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Excretion rate and extent of radioactivity in urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes